Sapigen Biologix plans a Rs 1,000 crore expansion in Bhubaneswar for new vaccines, seeking a 50% capital subsidy. The move aims to boost biotech in Eastern India and create jobs. Read more.
Pandorum Technologies partners with Bharat Biotech's Nucelion to boost exosome therapy manufacturing for Asia-Pacific. This strategic move aims to address unmet global clinical needs with regenerative medicine. Read more.
Hyderabad's Bharat Biotech partners with Pandorum Technologies to develop a breakthrough hydrogel-based regenerative therapy for corneal blindness. This collaboration aims to address a major unmet medical need in India and globally. Read more about this i
Enforcement Directorate attaches luxury London property worth Rs 150 crore near Buckingham Palace in a Rs 5,000 crore bank fraud case involving Sterling Biotech promoters. Read the full investigation details.
Vivek Ramaswamy breaks silence on racial attacks and fraud allegations. His campaign details his biotech success with Roivant Sciences and FDA-approved drugs. Read the full story.
Fermenta Biotech Ltd. has been recognized as one of India's Best Workplaces in Pharmaceuticals, Healthcare & Biotech 2024 by Great Place To Work. Discover what makes their culture stand out.
Orange Biotech Private Limited unveils a nationwide PCD pharma franchise with high-profit margins, monopoly rights, and extensive product portfolio for entrepreneurs. Start your own pharma business today!
Concord Biotech's block deal, Ambuja Cements' acquisition, Paytm's new CEO, and Groww's funding round are among the top market movers today. Get the full analysis.
Biocon announces merger of its biologics subsidiary with the parent company and a major Rs 4,500 crore fundraise. Explore the strategic shift and its impact on India's biotech sector.
Odisha's Science Dept invites faculty & researchers for biotech R&D grants up to Rs 30 lakh. Maximum 10 projects selected yearly. Submit applications before December 10 deadline.
Fugitive Sandesara brothers offer Rs 5,100 crore settlement, bringing total recovery to Rs 9,800 crore - far exceeding banks' Rs 6,700 crore demand. ED celebrates biggest PMLA recovery.
Supreme Court permits Sandesara brothers to settle massive bank fraud case with ₹5,100 crore payment. Historic decision marks first criminal case closure after settlement. Read full details.
Supreme Court approves ₹5,100 crore settlement by fugitive Sandesara brothers in massive bank fraud case. All criminal proceedings to be dropped upon payment completion by December 2025.
Supreme Court agrees to drop criminal proceedings against Sterling Biotech promoters in bank fraud case upon payment of Rs 5,100 crore by December 17, 2025. Full case details inside.
India's biotechnology sector is projected to become a $1.2 trillion industry by 2047, driven by vaccines, diagnostics, and bio-agriculture. Discover how this growth will transform healthcare and agriculture.
A US commission warns Congress of China's growing leverage in biotech, quantum computing, and legacy semiconductors, urging action to prevent supply chain weaponization. Read the full report.
South Korea is developing a $35 billion data center entirely designed, built, and operated by artificial intelligence. Scheduled for 2028 completion, this groundbreaking project marks a major leap in AI infrastructure.
Indian vaccine maker Bharat Biotech expands into high-growth CRDMO space with new subsidiary Nucelion Therapeutics, focusing on cutting-edge cell and gene therapies for cancer and rare diseases.
Indian biopharmaceutical leader Health Biotech Limited makes waves at CPhI Frankfurt 2025, showcasing innovative products and forging international partnerships to strengthen its global market position.
Federal health officials are accelerating efforts to bring cheaper biotech drugs to market, potentially transforming treatment access and creating new opportunities for Indian pharmaceutical companies.
In a significant setback for gene editing medicine, Intellia Therapeutics halts its Phase 3 ATTR trial following a serious liver adverse event in a patient receiving CRISPR-based treatment NZ-1.
Swiss pharmaceutical giant Novartis AG is finalizing a landmark acquisition of California-based Avidity Biosciences in a deal valuing the biotech firm at over $70 per share, potentially exceeding $1.7 billion, according to exclusive reports.